RTI Biologics Releases Corporate Social Responsibility Report

12/14/2011

• Wendy Crites Wacker, APR
• Director, Corporate Communications
• wwacker@rtix.com
• 386-418-8888 x4220

ALACHUA, Fla. (Dec. 2011) – RTI Biologics Inc. (RTI) (Nasdaq: RTIX), a leading provider of orthopedic and other biologic implants, produced its first corporate social responsibility report in 2011. The report covers the 2010 calendar year and includes information about the company’s employee relations, environmental, societal and economic impact.

As a company, RTI is committed to making a positive impact through its activities with employees, communities, the environment and all stakeholders. This report is a true testament to all RTI employees’ hard work and commitment. Not only does RTI want to provide safe, quality implants to patients and surgeons around the world but to do so in a responsible manner.

See RTI’s corporate social responsibility report here: http://www.rtix.com/about/corporate-social-responsibility/.

About RTI Biologics Inc.
RTI Biologics Inc. is a leading provider of sterile biologic implants for surgeries around the world with a commitment to advancing science, safety and innovation. RTI prepares human donated tissue and bovine tissue for transplantation through extensive testing and screening and using proprietary processes. These allograft and xenograft implants are used in orthopedic, dental and other specialty surgeries.

RTI’s innovations continuously raise the bar of science and safety for biologics – from being the first company to offer precision-tooled bone implants and assembled technology to maximize each gift of donation, to inventing validated sterilization processes that include viral inactivation steps. Two such processes – the BioCleanse® Tissue Sterilization Process and the Tutoplast® Tissue Sterilization Process – have a combined record of more than two million implants distributed with zero incidence of allograft-associated infection. These processes have been validated by tissue type to inactivate or remove viruses, bacteria, fungi and spores from the tissue while maintaining biocompatibility and functionality.

RTI’s worldwide corporate headquarters are located in Alachua, Fla., with international locations in Germany and France. The company is accredited by the American Association of Tissue Banks in the United States and is a member of AdvaMed.